Fingerprint
Dive into the research topics of 'A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
Alex A. Adjei*, Patricia LoRusso, Antoni Ribas, Jeffrey A. Sosman, Anna Pavlick, Grace K. Dy, Xiaofei Zhou, Esha Gangolli, Michelle Kneissl, Stephanie Faucette, Rachel Neuwirth, Viviana Bózon
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
28
Scopus
citations